- •Preface and Acknowledgments
- •Contents
- •Contributors
- •1: Embryology for Urologists
- •Introduction
- •Renal Development
- •Pronephros
- •Mesonephros
- •Metanephros
- •Development of the Collecting System
- •Critical Steps in Further Development
- •Anomalies of the Kidney
- •Renal Agenesis
- •Renal Aplasia
- •Renal Hypoplasia
- •Renal Ectopia
- •Renal Fusion
- •Ureteral Development
- •Anomalies of Origin
- •Anomalies of Number
- •Incomplete Ureteral Duplication
- •Complete Ureteral Duplication
- •Ureteral Ectopia
- •Embryology of Ectopia
- •Clinical Correlation
- •Location of Ectopic Ureteral Orifices – Male (in Descending Order According to Incidence)
- •Symptoms
- •Ureteroceles
- •Congenital Ureteral Obstruction
- •Pipestem Ureter
- •Megaureter-Megacystis Syndrome
- •Prune Belly Syndrome
- •Vascular Ureteral Obstructions
- •Division of the Urogenital Sinus
- •Bladder Development
- •Urachal Anomalies
- •Cloacal Duct Anomalies
- •Other Bladder Anomalies
- •Bladder Diverticula
- •Bladder Extrophy
- •Gonadal Development
- •Testicular Differentiation
- •Ovarian Differentiation
- •Gonadal Anomalies
- •Genital Duct System
- •Disorders of Testicular Function
- •Female Ductal Development
- •Prostatic Urethral Valves
- •Gonadal Duct Anomalies
- •External Genital Development
- •Male External Genital Development
- •Female External Genital Development
- •Anomalies of the External Genitalia
- •References
- •2: Gross and Laparoscopic Anatomy of the Upper Urinary Tract and Retroperitoneum
- •Overview
- •The Kidneys
- •The Renal Vasculature
- •The Renal Collecting System
- •The Ureters
- •Retroperitoneal Lymphatics
- •Retroperitoneal Nerves
- •The Adrenal Glands
- •References
- •3: Gross and Laparoscopic Anatomy of the Lower Urinary Tract and Pelvis
- •Introduction
- •Female Pelvis
- •Male Pelvis
- •Pelvic Floor
- •Urinary Bladder
- •Urethra
- •Male Urethra
- •Female Urethra
- •Sphincter Mechanisms
- •The Bladder Neck Component
- •The Urethral Wall Component
- •The External Urethral Sphincter
- •Summary
- •References
- •4: Anatomy of the Male Reproductive System
- •Testis and Scrotum
- •Spermatogenesis
- •Hormonal Regulation of Spermatogenesis
- •Genetic Regulation of Spermatogenesis
- •Epididymis and Ductus Deferens
- •Accessory Sex Glands
- •Prostate
- •Seminal Vesicles
- •Bulbourethral Glands
- •Penis
- •Erection and Ejaculation
- •References
- •5: Imaging of the Upper Tracts
- •Anatomy of the Upper Tracts and Introduction to Imaging Modalities
- •Introduction
- •Renal Upper Tract Basic Anatomy
- •Modalities Used for Imaging the Upper Tracts
- •Ultrasound
- •Radiation Issues
- •Contrast Issues
- •Renal and Upper Tract Tumors
- •Benign Renal Tumors
- •Transitional Cell Carcinoma
- •Renal Mass Biopsy
- •Renal Stone Disease
- •Ultrasound
- •Plain Radiographs and IVU
- •Renal Cystic Disease
- •Benign Renal Cysts
- •Hereditary Renal Cystic Disease
- •Complex Renal Cysts
- •Renal Trauma
- •References
- •Introduction
- •Pathophysiology
- •Susceptibility and Resistance
- •Epidemiological Breakpoints
- •Clinical Breakpoints
- •Pharmacodynamic Parameters
- •Pharmacokinetic Parameters
- •Fosfomycin
- •Nitrofurantoin
- •Pivmecillinam
- •b-Lactam-Antibiotics
- •Penicillins
- •Cephalosporins
- •Carbapenems
- •Aminoglycosides
- •Fluoroquinolones
- •Trimethoprim, Cotrimoxazole
- •Glycopeptides
- •Linezolid
- •Conclusion
- •References
- •7: An Overview of Renal Physiology
- •Introduction
- •Body Fluid Compartments
- •Regulation of Potassium Balance
- •Regulation of Acid–Base Balance
- •Diuretics
- •Suggested Reading
- •8: Ureteral Physiology and Pharmacology
- •Ureteral Anatomy
- •Modulation of Peristalsis
- •Ureteral Pharmacology
- •Conclusion
- •References
- •Introduction
- •Afferent Signaling Pathways
- •Efferent Signaling
- •Parasympathetic Nerves
- •Sympathetic Nerves
- •Vesico-Spinal-Vesical Micturition Reflex
- •Peripheral Targets
- •Afferent Signaling Mechanisms
- •Urothelium
- •Myocytes
- •Cholinergic Receptors
- •Muscarinic Receptors
- •Nicotinic Receptors
- •Adrenergic Receptors (ARs)
- •a-Adrenoceptors
- •b-Adrenoceptors
- •Transient Receptor Potential (TRP) Receptors
- •Phosphodiesterases (PDEs)
- •CNS Targets
- •Opioid Receptors
- •Serotonin (5-HT) Mechanisms
- •g-Amino Butyric Acid (GABA) Mechanisms
- •Gabapentin
- •Neurokinin and Neurokinin Receptors
- •Summary
- •References
- •10: Pharmacology of Sexual Function
- •Introduction
- •Sexual Desire/Arousal
- •Endocrinology
- •Steroids in the Male
- •Steroids in the Female
- •Neurohormones
- •Neurotransmitters
- •Dopamine
- •Serotonin
- •Pharmacological Strategies
- •CNS Drugs
- •Enzyme-inducing Antiepileptic Drugs
- •Erectile Function
- •Ejaculatory Function
- •Premature Ejaculation
- •Abnormal Ejaculation
- •Conclusions
- •References
- •Epidemiology
- •Calcium-Based Urolithiasis
- •Uric Acid Urolithiasis
- •Infectious Urolithiasis
- •Cystine-Based Urolithiasis
- •Aims
- •Who Deserves Metabolic Evaluation?
- •Metabolic Workup for Stone Producers
- •Medical History and Physical Examination
- •Stone Analysis
- •Serum Chemistry
- •Urine Evaluation
- •Urine Cultures
- •Urinalysis
- •Twenty-Four Hour Urine Collections
- •Radiologic Imaging
- •Medical Management
- •Conservative Management
- •Increased Fluid Intake
- •Citrus Juices
- •Dietary Restrictions
- •Restricted Oxalate Diet
- •Conservative Measures
- •Selective Medical Therapy
- •Absorptive Hypercalciuria
- •Thiazide
- •Orthophosphate
- •Renal Hypercalciuria
- •Primary Hyperparathyroidism
- •Hyperuricosuric Calcium Oxalate Nephrolithiasis
- •Enteric Hyperoxaluria
- •Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Distal Renal Tubular Acidosis
- •Chronic Diarrheal States
- •Thiazide-Induced Hypocitraturia
- •Idiopathic Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Hypomagnesiuric Calcium Nephrolithiasis
- •Gouty Diathesis
- •Cystinuria
- •Infection Lithiasis
- •Summary
- •References
- •12: Molecular Biology for Urologists
- •Introduction
- •Inherited Changes in Cancer Cells
- •VEGR and Cell Signaling
- •Targeting mTOR
- •Conclusion
- •References
- •13: Chemotherapeutic Agents for Urologic Oncology
- •Introduction
- •Bladder Cancer
- •Muscle Invasive Bladder Cancer
- •Metastatic Bladder Cancer
- •Conclusion
- •Prostate Cancer
- •Other Chemotherapeutic Drugs or Combinations for Treating HRPC
- •Conclusion
- •Renal Cell Carcinoma
- •Chemotherapy
- •Immunotherapy
- •Angiogenesis Inhibitor Drugs
- •Conclusion
- •Testicular Cancer
- •Stage I Seminoma
- •Stage I non-seminomatous Germ Cell Tumours (NSGCT)
- •Metastatic Germ Cell Tumours
- •Low-Volume Metastatic Disease (Stage II A/B)
- •Advanced Metastatic Disease
- •Salvage Chemotherapy for Relapsed or Refractory Disease
- •Conclusion
- •Penile Cancer
- •Side Effects of Chemotherapy
- •Conclusion
- •References
- •14: Tumor and Transplant Immunology
- •Antibodies
- •Cytotoxic and T-helper Cells
- •Immunosuppression
- •Induction Therapy
- •Maintenance Therapy
- •Rejection
- •Posttransplant Lymphoproliferative Disease
- •Summary
- •References
- •15: Pathophysiology of Renal Obstruction
- •Causes of Renal Obstruction
- •Effects on Prenatal Development
- •Prenatal Hydronephrosis
- •Spectrum of Renal Abnormalities
- •Renal Functional Changes
- •Renal Growth/Counterbalance
- •Vascular Changes
- •Inflammatory Mediators
- •Glomerular Development Changes
- •Mechanical Stretch of Renal Tubules
- •Unilateral Versus Bilateral
- •Limitations of Animal Models
- •Future Research
- •Issues in Patient Management
- •Diagnostic Imaging
- •Ultrasound
- •Intravenous Urography
- •Antegrade Urography and the Whitaker Test
- •Nuclear Renography
- •Computed Tomography
- •Magnetic Resonance Urography
- •Hypertension
- •Postobstructive Diuresis
- •References
- •Introduction
- •The Normal Lower Urinary Tract
- •Anatomy
- •Storage Function
- •Voiding Function
- •Neural Control
- •Symptoms
- •Flow Rate and Post-void Residual
- •Voiding Cystometry
- •Male
- •Female
- •Neurourology
- •Conclusions
- •References
- •17: Urologic Endocrinology
- •The Testis
- •Normal Androgen Metabolism
- •Epidemiological Aspects
- •Prostate
- •Brain
- •Muscle Mass and Adipose Tissue
- •Bones
- •Ematopoiesis
- •Metabolism
- •Cardiovascular System
- •Clinical Assessment
- •Biochemical Assessment
- •Treatment Modalities
- •Oral Preparations
- •Parenteral Preparations
- •Transdermal Preparations
- •Side Effects and Treatment Monitoring
- •Body Composition
- •Cognitive Decline
- •Bone Metabolism
- •The Kidneys
- •Endocrine Functions of the Kidney
- •Erythropoietin
- •Calcitriol
- •Renin
- •Paraneoplastic Syndromes
- •Hypercalcemia
- •Hypertension
- •Polycythemia
- •Other Endocrine Abnormalities
- •References
- •General Physiology
- •Prostate Innervation
- •Summary
- •References
- •Wound Healing
- •Inflammation
- •Proliferation
- •Remodeling
- •Principles of Plastic Surgery
- •Tissue Characteristics
- •Grafts
- •Flap
- •References
- •Lower Urinary Tract Symptoms
- •Storage Phase
- •Voiding Phase
- •Return to Storage Phase
- •Urodynamic Parameters
- •Urodynamic Techniques
- •Volume Voided Charts
- •Pad Testing
- •Typical Test Schedule
- •Uroflowmetry
- •Post Voiding Residual
- •Further Diagnostic Evaluation of Patients
- •Cystometry with or Without Video
- •Cystometry
- •Videocystometrography (Cystometry + Cystourethrography)
- •Cystometric Findings
- •Comment:
- •Measurements During the Storage Phase:
- •Measurements During the Voiding Phase:
- •Abnormal Function
- •Disorders of Sensation
- •Causes of Hypersensitive Bladder Sensation
- •Causes of Hyposensitive Bladder Sensation
- •Disorders of Detrusor Motor Function
- •Bladder Outflow Tract Dysfunction
- •Detrusor–Urethral Dyssynergia
- •Detrusor–Bladder Neck Dyssynergia
- •Detrusor–Sphincter Dyssynergia
- •Complex Urodynamic Investigation
- •Urethral Pressure Measurement
- •Technique
- •Neurophysiological Evaluation
- •Conclusion
- •References
- •Endoscopy
- •Cystourethroscopy
- •Ureteroscopy and Ureteropyeloscopy
- •Nephroscopy
- •Virtual Reality Simulators
- •Lasers
- •Clinical Application of Lasers
- •Condylomata Acuminata
- •Urolithiasis
- •Benign Prostatic Hyperplasia
- •Ureteral and Urethral Strictures
- •Conclusion
- •References
- •Introduction
- •The Prostatitis Syndromes
- •The Scope of the Problem
- •Category III CP/CPPS
- •The Goal of Treatment
- •Conservative Management
- •Drug Therapy
- •Antibiotics
- •Anti-inflammatories
- •Alpha blockers
- •Hormone Therapies
- •Phytotherapies
- •Analgesics, muscle relaxants and neuromodulators
- •Surgery
- •A Practical Management Plan
- •References
- •Orchitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment of Infectious Orchitis
- •Epididymitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation of Epididymitis
- •Treatment of Acute Epididymitis
- •Treatment of Chronic Epididymitis
- •Treatment of Spermatic Cord Torsion
- •Fournier’s Gangrene
- •Definition and Etiology
- •Risk Factors
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment
- •References
- •Fungal Infections
- •Candidiasis
- •Aspergillosis
- •Cryptococcosis
- •Blastomycosis
- •Coccidioidomycosis
- •Histoplasmosis
- •Radiographic Findings
- •Treatment
- •Tuberculosis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Schistosomiasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Filariasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Onchocerciasis
- •References
- •25: Sexually Transmitted Infections
- •Introduction
- •STIs Associated with Genital Ulcers
- •Herpes Simplex Virus
- •Diagnosis
- •Treatment
- •Chancroid
- •Diagnosis
- •Treatment
- •Syphilis
- •Diagnosis
- •Treatment
- •Lymphogranuloma Venereum
- •Diagnosis
- •Treatment
- •Chlamydia
- •Diagnosis
- •Treatment
- •Gonorrhea
- •Diagnosis
- •Treatment
- •Trichomoniasis
- •Diagnosis
- •Treatment
- •Human Papilloma Virus
- •Diagnosis
- •Treatment
- •Scabies
- •Diagnosis
- •Treatment
- •References
- •26: Hematuria: Evaluation and Management
- •Introduction
- •Classification of Hematuria
- •Macroscopic Hematuria
- •Microscopic Hematuria
- •Dipstick Hematuria
- •Pseudohematuria
- •Factitious Hematuria
- •Menstruation
- •Aetiology
- •Malignancy
- •Urinary Calculi
- •Infection and Inflammation
- •Benign Prostatic Hyperplasia
- •Trauma
- •Drugs
- •Nephrological Causes
- •Assessment
- •History
- •Examination
- •Investigations
- •Dipstick Urinalysis
- •Cytology
- •Molecular Tests
- •Blood Tests
- •Flexible Cystoscopy
- •Upper Urinary Tract Evaluation
- •Renal USS
- •KUB Abdominal X-Ray
- •Intravenous Urography (IVU)
- •Computed Tomography (CT)
- •Retrograde Urogram Studies
- •Magnetic Resonance Imaging (MRI)
- •Additional Tests and Renal Biopsy
- •Intractable Hematuria
- •Loin Pain Hematuria Syndrome
- •References
- •27: Benign Prostatic Hyperplasia (BPH)
- •Historical Background
- •Pathophysiology
- •Patient Assessment
- •Treatment of BPH
- •Watchful Waiting
- •Drug Therapy
- •Interventional Therapies
- •Conclusions
- •References
- •28: Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie´s Disease
- •Erectile Dysfunction
- •Introduction
- •Diagnosis
- •Basic Evaluation
- •Cardiovascular System and Sexual Activity
- •Optional Tests
- •Treatment
- •Medical Treatment
- •Oral Agents
- •Phosphodiesterase Type 5 (PDE 5) Inhibitors
- •Nonresponders to PDE5 Inhibitors
- •Apomorphine SL
- •Yohimbine
- •Intracavernosal and Intraurethral Therapy
- •Intracavernosal Injection (ICI) Therapy
- •Intraurethral Therapy
- •Vacuum Constriction Devices
- •Surgical Therapy
- •Conclusion
- •Peyronie´s Disease (PD)
- •Introduction
- •Oral Drug Therapy
- •Intralesional Drug Therapy
- •Iontophoresis
- •Radiation Therapy
- •Surgical Therapy
- •References
- •29: Premature Ejaculation
- •Introduction
- •Epidemiology
- •Defining Premature Ejaculation
- •Voluntary Control
- •Sexual Satisfaction
- •Distress
- •Psychosexual Counseling
- •Pharmacological Treatment
- •On-Demand Treatment with Tramadol
- •Topical Anesthetics
- •Phosphodiesterase Inhibitors
- •Surgery
- •Conclusion
- •References
- •30: The Role of Interventional Management for Urinary Tract Calculi
- •Contraindications to ESWL
- •Complications of ESWL
- •PCNL Access
- •Instrumentation for PCNL
- •Nephrostomy Drains Post PCNL
- •Contraindications to PCNL
- •Complications of PCNL
- •Semirigid Ureteroscopy
- •Flexible Ureteroscopy
- •Electrohydraulic Lithotripsy (EHL)
- •Ultrasound
- •Ballistic Lithotripsy
- •Laser Lithotripsy
- •Ureteric Stents
- •Staghorn Calculi
- •Lower Pole Stones
- •Horseshoe Kidneys and Stones
- •Calyceal Diverticula Stones
- •Stones and PUJ Obstruction
- •Treatment of Ureteric Colic
- •Medical Expulsive Therapy (MET)
- •Intervention for Ureteric Stones
- •Stones in Pregnancy
- •Morbid Obesity
- •References
- •Anatomy and Function
- •Pathophysiology
- •Management
- •Optical Urethrotomy/Dilatation
- •Urethral Stents
- •Preoperative Assessment
- •Urethroplasty
- •Anastomotic Urethroplasty
- •Substitution Urethroplasty
- •Grafts Versus Flaps
- •Oral Mucosal Grafts
- •Tissue Engineering
- •Graft Position
- •Conclusion
- •References
- •32: Urinary Incontinence
- •Epidemiology and Risk Factors
- •Pathophysiology
- •Urge Incontinence
- •Conservative Treatments
- •Pharmacotherapy
- •Invasive/ Surgical Therapies
- •Stress Urinary Incontinence
- •Male SUI Therapies
- •Female SUI Therapies
- •Mixed Urinary Incontinence
- •Conclusions
- •References
- •33: Neurogenic Bladder
- •Introduction
- •Examination and Diagnostic Tests
- •History and Physical Examination
- •Imaging
- •Urodynamics (UDS)
- •Evoked Potentials
- •Classifications
- •Somatic Pathways
- •Brain Lesions
- •Cerebrovascular Accident (CVA)
- •Parkinson’s Disease (PD)
- •Multiple Sclerosis
- •Huntington’s Disease
- •Dementias
- •Normal Pressure Hydrocephalus (NPH)
- •Tumors
- •Psychiatric Disorders
- •Spinal Lesions and Pathology
- •Intervertebral Disk Prolapse
- •Spinal Cord Injury (SCI)
- •Transverse Myelitis
- •Peripheral Neuropathies
- •Metabolic Neuropathies
- •Pelvic Surgery
- •Treatment
- •Summary
- •References
- •34: Pelvic Prolapse
- •Introduction
- •Epidemiology
- •Anatomy and Pathophysiology
- •Evaluation and Diagnosis
- •Outcome Measures
- •Imaging
- •Urodynamics
- •Indications for Management
- •Biosynthetics
- •Surgical Management
- •Anterior Compartment Repair
- •Uterine/Apical Prolapse
- •Enterocele Repair
- •Conclusion
- •References
- •35: Urinary Tract Fistula
- •Introduction
- •Urogynecologic Fistula
- •Vesicovaginal Fistula
- •Etiology and Risk Factors
- •Clinical Factors
- •Evaluation and Diagnosis
- •Pelvic Examination
- •Cystoscopy
- •Imaging
- •Treatment
- •Conservative Management
- •Surgical Management
- •Urethrovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Ureterovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Vesicouterine Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Uro-Enteric Fistula
- •Vesicoenteric Fistula
- •Pyeloenteric Fistula
- •Urethrorectal Fistula
- •References
- •36: Urologic Trauma
- •Introduction
- •Kidney
- •Expectant Management
- •Endovascular Therapy
- •Operative Intervention
- •Operative Management: Follow-up
- •Reno-Vascular Injuries
- •Pediatric Renal Injuries
- •Adrenal
- •Ureter
- •Diagnosis
- •Treatment
- •Delayed Diagnosis
- •Bladder and Posterior Urethra
- •Bladder Injuries: Initial Management
- •Bladder Injuries: Formal Repair
- •Anterior Urethral Trauma
- •Fractured Penis
- •Penile Amputation
- •Scrotal and Testicular Trauma
- •Imaging
- •CT-IVP (CT with Delayed Images)
- •Technique
- •Cystogram
- •Technique
- •Retrograde Urethrogram (RUG)
- •Technique
- •Retrograde Pyelogram (RPG)
- •Technique
- •One-Shot IVP
- •Technique
- •References
- •37: Bladder Cancer
- •Who Should Be Investigated?
- •Epidemiology
- •Risk Factors
- •Role of Screening
- •Signs and Symptoms
- •Imaging
- •Cystoscopy
- •Urine Tests
- •PDD-Assisted TUR
- •Pathology
- •NMIBC and Risk Groups
- •Intravesical Chemotherapy
- •Intravesical Immunotherapy
- •Immediate Cystectomy and CIS
- •Radical Cystectomy with Pelvic Lymph Node Dissection
- •sexual function-preserving techniques
- •Bladder-Preservation Treatments
- •Neoadjuvant Chemotherapy
- •Adjuvant Chemotherapy
- •Preoperative Radiotherapy
- •Follow-up After TUR in NMIBC
- •References
- •38: Prostate Cancer
- •Introduction
- •Epidemiology
- •Race
- •Geographic Variation
- •Risk Factors and Prevention
- •Family History
- •Diet and Lifestyle
- •Prevention
- •Screening and Diagnosis
- •Current Screening Recommendations
- •Biopsy
- •Pathology
- •Prognosis
- •Treatment of Prostate Cancer
- •Treatment for Localized Prostate Cancer (T1, T2)
- •Radical Prostatectomy
- •EBRT
- •IMRT
- •Brachytherapy
- •Treatment for Locally Advanced Prostate Cancer (T3, T4)
- •EBRT with ADT
- •Radical Prostatectomy
- •Androgen-Deprivation Therapy
- •Summary
- •References
- •39: The Management of Testis Cancer
- •Presentation and Diagnosis
- •Serum Tumor Markers
- •Primary Surgery
- •Testis Preserving Surgery
- •Risk Stratification
- •Surveillance Versus Primary RPLND
- •Primary RPLND
- •Adjuvant Treatment for High Risk
- •Clinical Stage 1 Seminoma
- •Risk-Stratified Adjuvant Treatment
- •Adjuvant Radiotherapy
- •Adjuvant Low Dose Chemotherapy
- •Primary Combination Chemotherapy
- •Late Toxicity
- •Salvage Strategies
- •Conclusion
- •References
- •Index
109
an ovErviEW of rEnal PHysiology
this results in the suppression of both thirst and |
Distribution of Potassium (internal potassium |
|||||||
AVP release. This leads to decreased permeabil- |
balance): Potassium homeostasis involves the |
|||||||
ity of the collecting duct to water, excretion of |
following processes: (1) gastrointestinal intake, |
|||||||
dilute urine, and the return of plasma osmolal- |
(2) internal distribution, and (3) excretion. There |
|||||||
ity to normal. |
appears to be little regulation of potassium uptake |
|||||||
AVP acts through a specific vasopressin type-2 |
by the gastrointestinal tract so that virtually all |
|||||||
receptor on the basolateral side of the collecting |
the ingested potassium is transferred into the |
|||||||
duct. This leads to an increase in intracellular |
extracellular fluid. The distribution of potassium |
|||||||
cyclic AMP, activation of protein kinase A, and |
within the body is critical for maintaining nor- |
|||||||
increased trafficking of aquaporin (water chan- |
mal serum potassium following normal dietary |
|||||||
nels) proteins to the luminal membrane to |
intake. For example, if one ingests 50 mEq of |
|||||||
increase water permeability of the cell.The great- |
potassium (three to four glasses of orange juice) |
|||||||
est stimulus to AVP release is an increase of |
a rise in serum potassium of 3.6 mEq/L would |
|||||||
plasma osmolality. AVP can also be stimulated |
occur if all the ingested potassium remained in |
|||||||
by ECF volume depletion (7–10%). Volume |
the extracellular fluid. However, because of rapid |
|||||||
depletion also causes the sensitivity of AVP |
redistribution into the intracellular compart- |
|||||||
release to increase and thus a lower plasma |
ment, the rise in plasma potassium is attenuated. |
|||||||
osmolality is tolerated in states of volume deple- |
To maintain potassium balance, however, all the |
|||||||
tion. Outside of these physiological stimuli for |
ingested potassium must eventually be excreted |
|||||||
AVP release,several non-physiological (but clini- |
by the kidneys. There are several factors which |
|||||||
cal important) stimuli exist. These include medi- |
affect potassium distribution between intracellu- |
|||||||
cations (selective serotonin release inhibitors, |
lar and extracellular compartments. |
|
|
|
||||
narcotic and chemotherapeutic drug), nausea |
1. Epinephrine: |
adrenergic |
receptors |
are |
||||
and vomiting, carcinomas, pulmonary and CNS |
||||||||
involved in |
the distribution of |
potassium. |
||||||
disorders. These non-physiological stimuli for |
||||||||
Stimulation |
of |
alpha adrenergic receptors |
||||||
AVP release can result in hyponatremia and |
||||||||
increases plasma potassium while stimula- |
||||||||
hypo-osmolality (the syndrome of inappropriate |
||||||||
tion of beta 2 |
receptors |
decreases |
plasma |
|||||
ADH release (SIADH)). Conversely, either the |
||||||||
potassium concentration. The use |
of |
beta |
||||||
inability of the hypothalamus to produce or |
||||||||
blockers such as propranolol can produce a |
||||||||
secrete AVP or the ability of the collecting duct |
||||||||
significant increase in serum potassium con- |
||||||||
to respond to AVP lead to the conditions of cen- |
||||||||
centration under certain circumstances. |
|
|||||||
tral or nephrogenic (respectively) diabetes insip- |
|
|||||||
2. Insulin: stimulates potassium uptake into the |
||||||||
idus (DI). In this state, the kidney continues to |
||||||||
cells by activating the Na, K-ATPase. |
|
|
||||||
excrete a large volume of dilute urine and patients |
|
|
||||||
need to either take synthetic AVP (for the central |
3. Aldosterone: similar to insulin, aldosterone |
|||||||
form of DI) or increase their intake of water to |
secretion is stimulated by high plasma potas- |
|||||||
keep pace with the renal losses. If this does not |
sium concentration and |
acts |
to promote |
|||||
occur, then increasing urine water losses will |
potassium |
uptake into muscle |
cells. This |
|||||
lead to hypernatremia and hyperosmolality. |
||||||||
action of aldosterone (to promote potassium |
||||||||
|
||||||||
Regulation of Potassium Balance |
uptake into muscle) is not as important as the |
|||||||
effect of insulin on potassium uptake by |
||||||||
|
muscle, or |
as |
important |
as the action of |
Potassium is abundant in the body totaling about 3,500 mEq for a 70 kg individual. Ninetyeight percent of potassium is located within the cell where the concentration averages between 100 and 150 mEq/L. Potassium is important for:
(1) volume regulation, (2) chemical reactions,
(3) cell division and growth, (4) acid–base status, (5) glucose uptake and glycogen synthesis, and (6) excitability and contractility of neuromuscular cells.
aldosterone on potassium transport by renal epithelial cells (see below).
4.Acid–base balance: Changes in the pH of the extracellular fluid alter intracellular pH and redistributes potassium. In acidemia, plasma potassium concentration increases because potassium moves out of the cells.In alkalemia, plasma potassium concentration falls because potassium moves into cells.
|
|
|
|
|
|
|
110 |
||
|
|
|
|
|
|
||||
|
|
|
Practical Urology: EssEntial PrinciPlEs and PracticE |
||||||
5. Exercise: During exercise skeletal muscle cells |
2. Aldosterone: Aldosterone stimulates sodium |
||||||||
release potassium and produces variable deg- |
reabsorption by the distal tubule and collect- |
||||||||
rees of hyperkalemia. Usually, these changes |
ing duct, and enhances potassium secretion |
||||||||
produce no symptoms and are reversed after |
by increasing activity of the Na, K-ATPase. |
||||||||
several minutes of rest.However,under certain |
3. Flow rate of tubule fluid: An increase in |
||||||||
circumstances a significant increase in plasma |
tubule fluid flow rate increases potassium |
||||||||
potassium concentration can occur such as the |
secretion. |
|
|
|
|
||||
individuals who are using beta blockers during |
4. Plasma flow rate: Flow rate influences potas- |
||||||||
exercise. |
sium secretion by the distal tubule and col- |
||||||||
Excretion of potassium by the kidneys: App- |
lecting duct. |
|
|
|
|
||||
roximately 92% of ingested potassium is excreted |
5. Plasma pH: Alkalemia increases potassium |
||||||||
by the kidney. The remaining 8% is excreted by |
secretion and acidemia decreases potassium |
||||||||
the gastrointestinal tract. Potassium is freely fil- |
secretion. |
|
|
|
|
||||
tered by the glomerulus and normally the uri- |
6. Sodium concentration of the tubule fluid: An |
||||||||
nary potassium excretion is 15% of the amount |
|||||||||
increase in the sodium concentration in the |
|||||||||
filtered. The proximal tubule reabsorbs about |
|||||||||
distal tubule fluid stimulates potassium secre- |
|||||||||
67% of the filtered load of potassium, whereas |
|||||||||
tion, whereas a fall has the opposite effect. |
|||||||||
the loop of Henle reabsorbs 20%. It is in the dis- |
|||||||||
|
|
|
|
|
|
||||
tal tubule and the collecting duct where regula- |
|
|
|
|
|
|
|||
tion of potassium secretion occurs. When |
Regulation of Acid–Base Balance |
||||||||
dietary intake is normal, potassium is secreted |
|||||||||
by these distal nephron segments, however, |
|
|
|
|
|
|
|||
when potassium intake is below normal potas- |
The body maintains the systemic pH in a nar- |
||||||||
sium reabsorption occurs. |
row range to permit normal metabolic func- |
||||||||
The mechanism by which potassium is |
tions. The CO2/HCO3 buffer system is the most |
||||||||
secreted by the principal cells of the collecting |
important buffer system in the body because it |
||||||||
duct is provided by an electrochemical gradi- |
is under the regulation of both the lungs and the |
||||||||
ent. The |
uptake of potassium via the Na, |
kidney. The relationship is characterized by the |
|||||||
K-ATPase in the basolateral membrane increases |
Henderson–Hasselbalch equation. |
||||||||
the potassium concentration within the cell, |
|
6.1+1og |
HCO |
3 ] |
|||||
and provides a (1) chemical gradient for potas- |
pH = |
|
[ |
|
|||||
0.03 PCO |
2 ) |
|
|
||||||
sium to exit across the apical membrane through |
( |
|
|
|
|||||
potassium |
channels. Sodium conductance at |
In the normal individual, metabolism of carbo- |
|||||||
the apical |
membrane depolarizes the apical |
||||||||
hydrates and fats produce large quantities of |
|||||||||
membrane relative to the basolateral membrane |
|||||||||
CO2. CO2 is in equilibrium with H2CO3, a volatile |
|||||||||
and thus |
provides an (2) electrical gradient |
||||||||
(lumen negative charge favoring potassium |
acid. In addition to volatile acids, metabolism of |
||||||||
amino acids produces nonvolatile acids. The |
|||||||||
excretion). |
|||||||||
metabolism of cysteine and methionine yields |
|||||||||
There are various factors which regulate |
|||||||||
sulfuric acid, whereas lysine, arginine, and histi- |
|||||||||
potassium secretion by the principal cells. |
|||||||||
dine produce hydrochloric acid. A normal diet |
|||||||||
1. Plasma potassium concentration: Plasma |
|||||||||
produces about 70–100 mmol/day of nonvolatile |
|||||||||
potassium concentration is an important |
acid. These acids then consume bicarbonate |
||||||||
determinant of potassium secretion by the |
from the ECF, and must be replenished in order |
||||||||
distal tubule and collecting duct. An increase |
to maintain acid–base balance. |
|
|
||||||
The kidney has a major role in replenishing |
|||||||||
in the plasma potassium concentration stim- |
|||||||||
bicarbonate loss. There are essentially two com- |
|||||||||
ulates the Na, K-ATPase, thereby raising |
|||||||||
ponents to renal bicarbonate generation. The |
|||||||||
intracellular potassium concentration and |
|||||||||
first involves the reabsorption of filtered bicar- |
|||||||||
increasing the chemical gradient for potas- |
bonate, and the second involves synthesis of new |
||||||||
sium secretion. |
bicarbonate. |
|
|
|
|
111
an ovErviEW of rEnal PHysiology
Reabsorption of Filtered Bicarbonate: Of the |
calcium concentration in blood is dependent |
|||||||
filtered load of bicarbonate (4,500 mEq/day), |
upon the plasma pH as hydrogen ions compete |
|||||||
approximately 85% is reabsorbed by the proxi- |
with calcium ions for binding by plasma pro- |
|||||||
mal tubule and most of the rest is reabsorbed by |
teins. In states of acidemia, hydrogen ions dis- |
|||||||
the loop of Henle and collecting duct less than |
place calcium from proteins, thereby increasing |
|||||||
1% is lost in the urine. |
|
|
|
|
the plasma concentration of free ionized cal- |
|||
Synthesis of New Bicarbonate: As discussed |
cium. In contrast, in states of alkalemia, hydro- |
|||||||
above, because dietary intake involves the con- |
gen ions are displaced from plasma protein |
|||||||
sumption of volatile acids, which amounts to |
binding sites and replaced by calcium ions, |
|||||||
about 70–100 mmol/day, we must excrete this |
thereby decreasing the plasma free ionized cal- |
|||||||
amount of acid daily to stay in acid–base bal- |
cium concentration. |
|||||||
ance. This is achieved primarily by the secretion |
Of the filtered load of calcium, approximately |
|||||||
of titratable acids (H PO |
, and NH +). In states |
99% of the free ionized calcium is reabsorbed by |
||||||
|
|
2 |
|
4 |
|
4 |
the nephron,the majority of which is reabsorbed |
|
of acidemia, the filtered load of phosphate is not |
||||||||
regulated and therefore has a limited capacity to |
by the proximal tubule (70%). The thick ascend- |
|||||||
excrete extra acid (30–50 mmol/day). However, |
ing limb is responsible for the reabsorption of |
|||||||
NH3 |
production in response to acidemia |
20% of the filtered load of calcium, and the dis- |
||||||
increases dramatically, therefore, becomes the |
tal tubule and collecting ducts combine to reab- |
|||||||
dominant pathway for acid excretion (NH +). |
sorb approximately 10% of the filtered load of |
|||||||
Urine |
NH + |
|
|
|
|
4 |
calcium. The net result is that approximately 1% |
|
excretion begins with glutamine |
||||||||
|
4 |
|
|
|
|
|
of the filter load is excreted into the urine. |
|
metabolism in the proximal tubule forming |
||||||||
NH . NH /NH + enters the lumen of the proxi- |
Calcium reabsorption occurs through a trans- |
|||||||
3 |
3 |
4 |
|
|
|
|
cellular or a paracellular pathway. In the proxi- |
|
mal tubule and, through a convoluted process, |
||||||||
enters the collecting duct as NH3 |
and traps H+ |
mal tubule and in the thick ascending limb, |
||||||
secreted by the H+-ATPase in the collecting duct. |
changes in sodium reabsorption alter calcium |
|||||||
It is the presence of NH |
3 |
which permits the H+ |
reabsorption in parallel. In contrast, in the distal |
|||||
to continue to be secreted by the collecting duct. |
tubule and collecting duct it appears that cal- |
|||||||
Without NH3 the lumen PH would decrease to a |
cium and sodium transport are independently |
|||||||
point where limiting gradient would exit and |
regulated.Therefore,changes in urinary calcium |
|||||||
prevent further excretion of H+. |
|
and sodium excretion do not always occur in |
||||||
A defect in renal excretion of H+ or in recla- |
parallel. For example, thiazide diuretics inhibit |
|||||||
mation of bicarbonate leads to a group of disor- |
NaCl transport by the distal tubule increasing |
|||||||
ders termed renal tubular acidosis. These |
sodium excretion but decreasing calcium excre- |
|||||||
disorders result in a metabolic acidosis as well as, |
tion. Factors that are associated with an increase |
|||||||
in some cases, a propensity to nephrolithiasis. |
in calcium excretion includes: A decrease in |
|||||||
|
|
|
|
|
|
|
parathyroid hormone (PTH) levels, ECF volume |
|
Regulation of Calcium and |
expansion, phosphate depletion, and metabolic |
|||||||
acidosis. Factors which are associated with a |
||||||||
|
|
|
|
|
|
|
||
Phosphate Balance |
|
decrease in calcium excretion include: An |
||||||
|
increase in PTH, ECF volume concentration, |
|||||||
|
|
|
|
|
|
|
phosphate loading metabolic alkalosis, and 1,25 |
|
Calcium: Calcium is importantly involved in |
(OH)2 D3 (vitamin D). |
|||||||
bone formation, subdivision and growth, blood |
Phosphate: The kidney is an important organ |
|||||||
coagulation, intracellular signaling, and excita- |
in the maintenance of phosphate homeostasis. |
|||||||
tion concentration coupling. The following will |
Phosphate is an important component in nucle- |
|||||||
be limited to the renal handling of calcium. In |
otides, ATP, and it is an important component of |
|||||||
the blood, approximately 50% of the calcium in |
bone. The proximal tubule reabsorbs approxi- |
|||||||
plasma is present in a free ionized form. The |
mately 80% of the phosphate filtered load, and |
|||||||
majority of ionized calcium is bound to plasma |
the distal tubule reabsorbs approximately 10%. |
|||||||
proteins, primarily albumin, and a very small |
The loop of Henle and the collecting duct have |
|||||||
percent is complexed through several anions, |
an insignificant contribution to phosphate reab- |
|||||||
including HCO3, PO4, and SO4. The free ionized |
sorption. Phosphate reabsorption across the |
|
|
112 |
|
|
|
|
|
Practical Urology: EssEntial PrinciPlEs and PracticE |
apical membrane of the proximal tubule occurs |
prevention has been the focus of much research. |
|
by sodium phosphate cotransport mechanism. |
Although mannitol has been tested in animal |
|
PTH is an important regulator of phosphate |
models of acute renal failure, its efficacy in |
|
excretion. PTH increases cyclic AMP production |
human acute renal failure is controversial and it |
|
and inhibits phosphate reabsorption by the |
cannot be recommended for this purpose. |
|
proximal tubule. Other factors which increase |
Infusions of mannitol are used to lower the ele- |
|
phosphate excretion include phosphate loading, |
vated intracranial pressure of cerebral edema |
|
ECF volume expansion, glucocorticoids, and |
associated with tumors, neurosurgical proce- |
|
acidosis. Other factors which are important in |
dures, or other conditions. Osmotic agents cause |
|
decreasing phosphate excretion include phos- |
the redistribution of body fluid, increase urine |
|
phate depletion, ECF volume contraction, and |
flow rate, and accelerate the renal elimination of |
|
alkalosis. |
filtered solutes. |
|
|
|
Carbonic Anhydrase Inhibitors: Carbonic |
Diuretics |
anhydrase facilitates the reabsorption of sodium |
|
bicarbonate. This enzyme is located primarily in |
||
|
|
the proximal tubule and represents the major |
Diuretics produce an increase in urine output |
site of action. The degree of natriuresis is not as |
|
by increasing sodium excretion (natriuresis). |
great as expected for the same reason as dis- |
|
Various classes of diuretics affect specific |
cussed with osmotic diuretics (i.e., distal reab- |
|
nephron segments.The site of action determines |
sorption of sodium delivered). Acetazolamide is |
|
the magnitude of natriuresis. For example, in |
used effectively to treat chronic open-angle |
|
general, proximal acting diuretics such as car- |
glaucoma. Since the aqueous humor has a high |
|
bonic anhydrase inhibitors, or osmotic diuretics |
bicarbonate concentration, these drugs can be |
|
are weak diuretics because the more distal |
used to reduce aqueous humor formation. |
|
nephron segments reabsorb the increase in |
Acetazolamide is also used to prevent and treat |
|
sodium and chloride delivered to it.On the other |
acute mountain sickness, to alkalinize the urine, |
|
hand, the more distal acting diuretics like loop |
and to treat metabolic alkalosis. |
|
diuretics are potent diuretics. Diuretics gain |
Loop Diuretics: Loop diuretics primarily |
|
access to the tubule fluid by glomerular filtra- |
inhibits sodium reabsorption by the thick |
|
tion, secretion by organic anions and cationic |
ascending limb by blocking the Na-2Cl-1K |
|
secretory mechanism located in the proximal |
cotransport mechanism located in the apical |
|
tubule. By gaining access through the tubule |
membrane of these cells. This class of diuretics |
|
fluid they can exert their action by interacting |
exert a potent inhibition of sodium reabsorp- |
|
with transport mechanism located in the apical |
tion by the thick ascending limb because it not |
|
membrane of nephron segments. |
only inhibits sodium transport by the thick |
|
Osmotic Diuretics: Osmotic diuretics such as |
ascending limb, but it also impairs dilution and |
|
mannitol or glucose inhibit reabsorption of sol- |
concentrating ability (one function of the thick |
|
ute and water by altering osmotic forces along |
ascending limb is to produce a hypertonic med- |
|
the nephron. In addition, inhibition of sodium |
ullary interstitium). Inhibition of transport by |
|
reabsorption by the more proximal nephron, |
furosemide decreases tonicity of the intersti- |
|
allows more sodium to be delivered to and |
tium. Furosemide, torasemide ethacrynic acid |
|
absorbed by the thick ascending limb. This reab- |
may increase renal blood flow for brief intervals |
|
sorptive response by the distal segments limits |
during which urinary excretion of prostaglan- |
|
the degree of natriuresis seen with osmotic |
din E is elevated. Intravenous injections of furo- |
|
diuretics. Mannitol is usually the drug of choice |
semide reduce pulmonary arterial pressure and |
|
among osmotic agents. It is a common clinical |
peripheral venous compliance. Indomethacin, |
|
impression that mannitol improves renal hemo- |
an inhibitor of prostaglandin synthesis, inter- |
|
dynamics in a variety of situations of impend- |
feres with all these actions.Vascular phenomena |
|
ing or incipient acute renal failure (rapid |
of this sort occurring in the kidney and else- |
|
reduction in glomerular filtration rate). The |
where precede the onset of diuresis. The thera- |
|
incidence of acute renal failure in hospitalized |
peutic value of loop diuretics in pulmonary |
|
patients is significant and associated with an |
edema may be attributable in part to stimula- |
|
increase in morbidity and mortality. Thus its |
tion of prostaglandin synthesis in the lung. The |
113
an ovErviEW of rEnal PHysiology
greater efficacy of loop agents often enables |
calcium excretion,they are used in the treatment |
|
their successful use in evoking diuresis in edem- |
of calcium nephrolithiaisis and osteoporosis. |
|
atous patients with disturbances of cardiovas- |
Thiazide diuretics are also used to in the treat- |
|
cular, renal, or hepatic origin. For example, an |
ment of patients with nephrogenic diabetes |
|
oliguric patient whose GFR is only 10% of nor- |
insipidus. In this disorder, the tubules are unre- |
|
mal derives no benefit from a thiazide but may |
sponsive to vasopressin and therefore these |
|
respond well to a large dose of a loop diuretic. In |
patients undergo a water diuresis. Often the vol- |
|
addition, furosemide is an important adjunct in |
ume of dilute urine excreted is large enough to |
|
the treatment of acute pulmonary edema. The |
lead to intravascular volume depletion if the |
|
drug increases pulmonary and peripheral |
excreted volume is not matched by adequate |
|
venous compliance, thereby affording rapid |
intake of fluid. Chronic administration of thiaz- |
|
relief,and then maintains these beneficial effects |
ides increases the urine osmolality and reduces |
|
by reducing the plasma volume. The initial vas- |
urine flow in this condition. The mechanism |
|
cular effects are not linked to actions on the |
hinges on the excretion of sodium and hence |
|
renal tubule (venodilatation occurs in anephric |
removal of sodium from the ECF, an action that |
|
patients). Because of the effect of loop diuretics |
inevitably contracts ECF volume. The proximal |
|
in inducing an increase in calcium excretion, |
tubule then avidly reabsorbs sodium. Urine flow |
|
they are used to lower serum calcium concen- |
rate diminishes and urine osmolality rises when |
|
trations in patients with hypercalcemia. Isoto- |
sodium transport in the distal convoluted tubule |
|
nic saline is often coadministered to maintain |
is inhibited by the diuretic. Drug therapy in this |
|
the glomerular filtration rate. Loop diuretics |
instance is most effective in combination with |
|
increase K+ excretion and thus are useful in the |
dietary salt restriction. |
|
treatment of acute and chronic hyperkalemia. |
Potassium-Sparing Diuretics: In this group are |
|
Thiazide Diuretics: Thiazide diuretics are |
two types of diuretics which inhibit potassium |
|
organic anions which are filtered and secreted |
secretion. Spironolactone acts by antagonizing |
|
by the proximal tubule. They inhibit sodium |
aldosterone action on the principal cell of the |
|
transport by the distal convoluted tubule, or that |
collecting duct. Aldosterone increases sodium |
|
portion of the distal tubule just beyond the thick |
absorption and potassium secretion by increas- |
|
ascending limb. These diuretics block a sodium |
ing the number of functional sodium and potas- |
|
chloride cotransport mechanism located in the |
sium channels in the apical membrane, as well |
|
apical or luminal membranes of these cells. All |
as increasing the number of basolateral Na, |
|
of the thiazides act in the same way, with the dif- |
K-ATPase pumps. Aldosterone blocks this effect |
|
ferences among them attributable largely to |
and prevents sodium absorption and potassium |
|
pharmacokinetic |
characteristics and inherent |
secretion. Amiloride and triamterene are com- |
carbonic anhydrase inhibitory activity. In gen- |
pounds which represent a second class of diuret- |
|
eral, these agents are used in the treatment of |
ics which antagonize potassium secretion. The |
|
hypertension, CHF and in other conditions |
mechanism by which these diuretics inhibit |
|
when reduction of ECF volume is beneficial. |
potassium secretion is through inhibition of |
|
Reduction of blood pressure in patients with |
sodium channels located in the apical mem- |
|
hypertension results, in part, from contraction |
branes of principal cells. By blocking these |
|
of ECF volume. This occurs acutely, leading to a |
channels they block the electrical gradient for |
|
decrease in cardiac output with compensatory |
potassium secretion. Depletion of body potas- |
|
elevation of peripheral resistance. Vasocon- |
sium with or without significant lowering of |
|
striction then subsides enabling cardiac output |
serum potassium concentration (only 2% of |
|
to return to normal values. Augmented synthe- |
total body potassium is present in ECF) is prob- |
|
sis of vasodilator prostaglandins is reported and |
ably the most common side effect of diuretic |
|
may be a crucial factor for long-term main- |
therapy. Hypokalemia of sufficient magnitude |
|
tenance of a lower pressure, even though ECF |
creates many problems and may be life threat- |
|
volume tends to return toward normal. In addi- |
ening. These problems may include impairment |
|
tion to treatment of edematous disorders and |
of neuromuscular function, cardiac arrhythmia, |
|
hypertension,thiazide diuretics have been found |
intestinal disturbances, and partial loss of the |
|
effective in the treatment of other disorders. |
ability to concentrate urine. Predisposition of |
|
Because thiazide |
diuretics decrease renal |
diuretics to potassium wasting is especially |